DVL1 and triple-negative breast carcinoma: Moreover, our results are the first to demonstrate that SIRT-1 and HDACs regulate DVL-1 acetylation levels and pharmacological inhibition of these lysine deacetylases results in altered acetylation levels of DVL-1 in two triple-negative breast cancer cell lines.